\BOOKMARK [0][-]{chapter*.2}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.3}{Acknowledgements}{}% 2
\BOOKMARK [0][-]{chapter*.4}{Declarations}{}% 3
\BOOKMARK [0][-]{chapter*.5}{Submitted Abstracts}{}% 4
\BOOKMARK [0][-]{chapter*.6}{Associated Publications}{}% 5
\BOOKMARK [0][-]{chapter*.7}{Contents}{}% 6
\BOOKMARK [0][-]{chapter*.9}{List of Figures}{}% 7
\BOOKMARK [0][-]{chapter*.10}{List of Tables}{}% 8
\BOOKMARK [0][-]{chapter*.11}{Abbreviations}{}% 9
\BOOKMARK [0][-]{chapter.1}{Cross-tissue comparison of chromatin accessibility, gene expression signature and immunophenotypes in psoriatic arthritis}{}% 10
\BOOKMARK [1][-]{section.1.1}{Introduction}{chapter.1}% 11
\BOOKMARK [1][-]{section.1.2}{Results}{chapter.1}% 12
\BOOKMARK [2][-]{subsection.1.2.1}{PsA patients cohort description and datasets}{section.1.2}% 13
\BOOKMARK [2][-]{subsection.1.2.2}{Differences in the chromatin accessibility landscape between circulating and SF immune cells}{section.1.2}% 14
\BOOKMARK [2][-]{subsection.1.2.3}{Differential gene expression analysis in paired circulating and synovial immune cells}{section.1.2}% 15
\BOOKMARK [1][-]{section.1.3}{Discussion}{chapter.1}% 16
\BOOKMARK [0][-]{section.1.3}{Appendices}{}% 17
\BOOKMARK [0][-]{appendix.A}{Establishment of methods to assess genome-wide chromatin accessibility}{}% 18
